VistaGen Therapeutics (VTGN) Misses Q3 EPS by 22c

VistaGen Therapeutics (NASDAQ: VTGN) reported Q3 EPS of ($0.22). Revenue for the quarter came in at $410 thousand.

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• Burry doubles down on Nebius short after stock surges 34% on earnings
• Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
• Bit Digital (BTBT) Misses Q2 EPS by 27c